A Phase IB Pilot Trial of Herpesvirus Treatment in Idiopathic
... 1.2. A viral etiology of IPF was first suspected more than half a century ago, but identification of an important role for viruses in IPF pathogenesis has been challenging(2). In 2003, our group used a PCR strategy for identification of all known herpesviruses in lung tissue samples and found that 9 ...
... 1.2. A viral etiology of IPF was first suspected more than half a century ago, but identification of an important role for viruses in IPF pathogenesis has been challenging(2). In 2003, our group used a PCR strategy for identification of all known herpesviruses in lung tissue samples and found that 9 ...
Myotonic Dystrophy is an autosomally dominant inherited disease
... cases of affected children born to asymptomatic parents show that more research needs to be done about how DM is inherited (4). Biochemistry and Molecular Biology: While it has been known that Myotonic Dystrophy 1 (DM 1) arises from a mutation in the Myotonic Dystrophy Protein Kinase (DMPK) gene and ...
... cases of affected children born to asymptomatic parents show that more research needs to be done about how DM is inherited (4). Biochemistry and Molecular Biology: While it has been known that Myotonic Dystrophy 1 (DM 1) arises from a mutation in the Myotonic Dystrophy Protein Kinase (DMPK) gene and ...
MS-Word format
... the children terms of seed (PO:0009010). Also explain why this number is not the same as you see next to the term seed (PO:0009010). Hint: There are two types of associations in the ontology: direct associations, which are directly associated to the term for which a phenotype has been characterized ...
... the children terms of seed (PO:0009010). Also explain why this number is not the same as you see next to the term seed (PO:0009010). Hint: There are two types of associations in the ontology: direct associations, which are directly associated to the term for which a phenotype has been characterized ...
Familial Adenomatous Polyposis (FAP)
... Scientists are working on ways to put a correct copy of the FAP gene into the bowel wall. This is called “gene therapy”. Doctors are also looking at non-surgical ways to stop polyps growing, such as drug treatment. These may offer a way to treat FAP without surgery in the future. At the moment, the ...
... Scientists are working on ways to put a correct copy of the FAP gene into the bowel wall. This is called “gene therapy”. Doctors are also looking at non-surgical ways to stop polyps growing, such as drug treatment. These may offer a way to treat FAP without surgery in the future. At the moment, the ...
The Cruelest Cure? Ethical Issues in the Implementation
... often seems to stem from the fact that this set of techniques evokes distress (albeit temporary), rather than soothes it, as one might intuitively expect a treatment for anxiety to do. More specifically, as Feeney, Hembree, and Zoellner (2003) and Prochaska and Norcross (1999) have discussed, widesp ...
... often seems to stem from the fact that this set of techniques evokes distress (albeit temporary), rather than soothes it, as one might intuitively expect a treatment for anxiety to do. More specifically, as Feeney, Hembree, and Zoellner (2003) and Prochaska and Norcross (1999) have discussed, widesp ...
Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia
... Three issues must be considered when evaluating genotype-phenotype association studies in sickle cell anemia. First, most genotype-phenotype association studies have not integrated the numerous clinical and laboratory dimensions of the disease into a single measure of disease severity. By modeling t ...
... Three issues must be considered when evaluating genotype-phenotype association studies in sickle cell anemia. First, most genotype-phenotype association studies have not integrated the numerous clinical and laboratory dimensions of the disease into a single measure of disease severity. By modeling t ...
Further genetic evidence suggesting a role for the
... quantitative trait loci (QTL) for bone mineral density (BMD) [11–20], strongly suggesting that the genetic effect for common variation of the phenotype is under polygenic control. The 3p14-p21 region of the human genome has been identified as one of the most replicated QTLs for BMD in multiple studie ...
... quantitative trait loci (QTL) for bone mineral density (BMD) [11–20], strongly suggesting that the genetic effect for common variation of the phenotype is under polygenic control. The 3p14-p21 region of the human genome has been identified as one of the most replicated QTLs for BMD in multiple studie ...
Treatment Choice in Psychological Therapies and Counselling
... confusing for the non-specialist. Whilst it is not practicable to give a working definition of every separate therapy, we have listed the main types of psychological therapies widely used in the NHS. In addition, there are some therapies which, whilst not yet widely available, have been the subject ...
... confusing for the non-specialist. Whilst it is not practicable to give a working definition of every separate therapy, we have listed the main types of psychological therapies widely used in the NHS. In addition, there are some therapies which, whilst not yet widely available, have been the subject ...
(FISH) or Immunohistochemistry (IHC)
... thyroid, lung, salivary gland, stomach, colon and prostate cancer, it has been reported that approximately one-third of breast cancer patients overexpress HER-2/neu. This overexpression appears to be associated with more aggressive disease and usually results from amplification (multiple extra copie ...
... thyroid, lung, salivary gland, stomach, colon and prostate cancer, it has been reported that approximately one-third of breast cancer patients overexpress HER-2/neu. This overexpression appears to be associated with more aggressive disease and usually results from amplification (multiple extra copie ...
Medications and Dizziness
... associated dizziness have shown significantly better outcomes than patients who were not medicated.16 Meniere’s Disease Diuretics can significantly decrease the frequency and severity of Meniere’s attacks.14,17,18 The combination of medication and reduced dietary sodium is thought to decrease endoly ...
... associated dizziness have shown significantly better outcomes than patients who were not medicated.16 Meniere’s Disease Diuretics can significantly decrease the frequency and severity of Meniere’s attacks.14,17,18 The combination of medication and reduced dietary sodium is thought to decrease endoly ...
Fragile X Syndrome
... The Fragile X Syndrome (FXS) is a genetic disease inherited through the X chromosome, which was described for the first time in 1943 by Martin and Bell1. It is actually considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. Most ...
... The Fragile X Syndrome (FXS) is a genetic disease inherited through the X chromosome, which was described for the first time in 1943 by Martin and Bell1. It is actually considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. Most ...
draft nhmrc guidelines and discussion paper on xenotransplantation
... animal-to-animal studies will be carried out in parallel to animal-to-human transplants as the science progresses. The Discussion Paper states that there may be an “ill-defined point at which little or no further progress can be made without proceeding to a human clinical trial” (page 59, 5.6.1, las ...
... animal-to-animal studies will be carried out in parallel to animal-to-human transplants as the science progresses. The Discussion Paper states that there may be an “ill-defined point at which little or no further progress can be made without proceeding to a human clinical trial” (page 59, 5.6.1, las ...
Oral Rehydration Therapy vs IV Therapy in US
... CeraLyte® 70 and CeraLyte® 50 have the lowest osmolarity. CeraLyte® 70, CeraLyte® 50, and CeraLyte® 90 have greater amounts of carbohydrate than the WHO/Unicef ORS and more than other pediatric oral rehydration solutions. The mixed chain rice-carbohydrate in CeraLyte® means more effective and effici ...
... CeraLyte® 70 and CeraLyte® 50 have the lowest osmolarity. CeraLyte® 70, CeraLyte® 50, and CeraLyte® 90 have greater amounts of carbohydrate than the WHO/Unicef ORS and more than other pediatric oral rehydration solutions. The mixed chain rice-carbohydrate in CeraLyte® means more effective and effici ...
Possibilities and Limitations of Genetic Engineering
... a non-plant species, such as a bacterium. In alfalfa, the most commonly used method of gene transfer is Agrobacterium tumefaciens mediated gene transfer. A. tumefaciens is a naturally occurring soil bacterium that causes grown gall disease in many ornamental and fruit plants. The bacterium enters th ...
... a non-plant species, such as a bacterium. In alfalfa, the most commonly used method of gene transfer is Agrobacterium tumefaciens mediated gene transfer. A. tumefaciens is a naturally occurring soil bacterium that causes grown gall disease in many ornamental and fruit plants. The bacterium enters th ...
Final published version
... added to a final concentration of 1% (wt/vol), and pH was kept at 6.5 by the automatic addition of 10 M NaOH. Anaerobic conditions were attained by flushing sterile argon through the medium for 1 h preceding inoculation. Strains engineered for the production of mannitol and 2,3-butanediol were grown ...
... added to a final concentration of 1% (wt/vol), and pH was kept at 6.5 by the automatic addition of 10 M NaOH. Anaerobic conditions were attained by flushing sterile argon through the medium for 1 h preceding inoculation. Strains engineered for the production of mannitol and 2,3-butanediol were grown ...
Classification for a Phenotype
... further subclassification into genetic (familial) and nongenetic (nonfamilial) groups. Both classifications continue to exclude specific heart muscle disease (resulting from coronary, hypertensive, valvular, and congenital heart disease) from consideration as a cardiomyopathic disorder. There is no den ...
... further subclassification into genetic (familial) and nongenetic (nonfamilial) groups. Both classifications continue to exclude specific heart muscle disease (resulting from coronary, hypertensive, valvular, and congenital heart disease) from consideration as a cardiomyopathic disorder. There is no den ...
Gene Section FOXP3 (forkhead box P3) Atlas of Genetics and Cytogenetics
... used the GeneGo MetaCore knowledgebase to analyze genes that related to ErbB2 signaling pathway, we found that FOXP3 downregulated 10 genes in this pathway. With the notable exception of b-Myb and c-Myb, the down-regulation is not likely related to FoxP3mediated ErbB2 repression, as they are not kno ...
... used the GeneGo MetaCore knowledgebase to analyze genes that related to ErbB2 signaling pathway, we found that FOXP3 downregulated 10 genes in this pathway. With the notable exception of b-Myb and c-Myb, the down-regulation is not likely related to FoxP3mediated ErbB2 repression, as they are not kno ...
NORTHERN ILLINOIS UNIVERSITY The Effects of Land and Aquatic
... nineteen articles were approved to correctly answer the question "should resistance training be used as an intervention for the treatment of gait dysfunction in children with spastic cerebral palsy?" (Lehman, 2008). After reviewing the evidence collected it was ruled that there are no disadvantages ...
... nineteen articles were approved to correctly answer the question "should resistance training be used as an intervention for the treatment of gait dysfunction in children with spastic cerebral palsy?" (Lehman, 2008). After reviewing the evidence collected it was ruled that there are no disadvantages ...
Spleen Therapy in Practice
... responsible for important functions in the body’s immune system. Whereas immature T lymphocytes from the bone marrow are matured into helper, suppressor and killer cells in the thymus, cell training in the spleen is directed more towards B lymphocytes and antibodies. The T lymphocytes pass on their ...
... responsible for important functions in the body’s immune system. Whereas immature T lymphocytes from the bone marrow are matured into helper, suppressor and killer cells in the thymus, cell training in the spleen is directed more towards B lymphocytes and antibodies. The T lymphocytes pass on their ...
IDF Guide for Nurses - Immune Deficiency Foundation
... therapy for primary and secondary immunodeficiencies in those patients who do not make sufficient amounts of specific antibodies to adequately protect themselves from infectious diseases and those whose antibodies do not function correctly or those people with poor immunologic memory. Two examples of p ...
... therapy for primary and secondary immunodeficiencies in those patients who do not make sufficient amounts of specific antibodies to adequately protect themselves from infectious diseases and those whose antibodies do not function correctly or those people with poor immunologic memory. Two examples of p ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.